Related references
Note: Only part of the references are listed.Evolutionary crossroads: morphological heterogeneity reflects divergent intra-clonal evolution in a case of high-grade B-cell lymphoma
Valentina Tabanelli et al.
HAEMATOLOGICA (2020)
Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734
Chevaun D. Morrison-Smiths et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma
V Moreno et al.
ANNALS OF ONCOLOGY (2020)
Targeting BET bromodomain proteins in cancer: The example of lymphomas
Filippo Spriano et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors
Sarina A. Piha-Paul et al.
JNCI CANCER SPECTRUM (2020)
The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models
Stuart W. Hicks et al.
HAEMATOLOGICA (2019)
Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses
Luciano Cascione et al.
HAEMATOLOGICA (2019)
The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents
Filippo Spriano et al.
CLINICAL CANCER RESEARCH (2019)
Bromodomains: a new target class for drug development
Andrea G. Cochran et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors
Sarina A. Piha-Paul et al.
CLINICAL CANCER RESEARCH (2019)
The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer
Yuqian Yan et al.
EMBO MOLECULAR MEDICINE (2019)
Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma
Stefanie N. Meyer et al.
IMMUNITY (2019)
CCS1477: A Novel Small Molecule Inhibitor of p300/CBP Bromodomain for the Treatment of Acute Myeloid Leukaemia and Multiple Myeloma
Nigel Brooks et al.
BLOOD (2019)
Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in Multiple Myeloma
Katie Ryan et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease
Luca Aresu et al.
HAEMATOLOGICA (2019)
CREBBP/EP300 Bromodomain Inhibition Affects the Proliferation of AR-Positive Breast Cancer Cell Lines
Veronica Garcia-Carpizo et al.
MOLECULAR CANCER RESEARCH (2019)
BET Proteins as Targets for Anticancer Treatment
Anastasios Stathis et al.
CANCER DISCOVERY (2018)
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors
Jeremy Lewin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
Chiara Tarantelli et al.
CLINICAL CANCER RESEARCH (2018)
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
Loren M. Lasko et al.
NATURE (2017)
Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors
Hana Janouskova et al.
NATURE MEDICINE (2017)
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma
Elena Bernasconi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors
Tammie C. Yeh et al.
CLINICAL CANCER RESEARCH (2017)
SIFT missense predictions for genomes
Robert Vaser et al.
NATURE PROTOCOLS (2016)
Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression
Hideaki Ogiwara et al.
CANCER DISCOVERY (2016)
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas
E. Gaudio et al.
ANNALS OF ONCOLOGY (2016)
Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300
Terry D. Crawford et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members
Simon J. Hogg et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes
Michela Boi et al.
ONCOTARGET (2016)
Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma
Andrew R. Conery et al.
ELIFE (2016)
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
Celine Berthon et al.
LANCET HAEMATOLOGY (2016)
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
Sandy Amorim et al.
LANCET HAEMATOLOGY (2016)
The Ensembl Variant Effect Predictor
William McLaren et al.
GENOME BIOLOGY (2016)
Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy
Sarah Picaud et al.
CANCER RESEARCH (2015)
The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
Michela Boi et al.
CLINICAL CANCER RESEARCH (2015)
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses
Ariane Hammitzsch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response
Afua Adjeiwaa Mensah et al.
Oncotarget (2015)
Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B- cell Lymphoma
Sally E. Trabucco et al.
CLINICAL CANCER RESEARCH (2015)
[1,2,4]Triazolo[4,3-a]phthalazines: Inhibitors of Diverse Bromodomains
Oleg Fedorov et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors
Michele Ceribelli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
Bjoern Chapuy et al.
CANCER CELL (2013)
The design and synthesis of 5-and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains
Duncan Hay et al.
MEDCHEMCOMM (2013)
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
Alexandre Puissant et al.
CANCER DISCOVERY (2013)
Targeting Epigenetic Readers in Cancer
Mark A. Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Place your BETs: the therapeutic potential of bromodomains
R. K. Prinjha et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2012)
3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands
David S. Hewings et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Inactivating mutations of acetyltransferase genes in B-cell lymphoma
Laura Pasqualucci et al.
NATURE (2011)
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Ryan D. Morin et al.
NATURE (2011)
A framework for variation discovery and genotyping using next-generation DNA sequencing data
Mark A. DePristo et al.
NATURE GENETICS (2011)
A method and server for predicting damaging missense mutations
Ivan A. Adzhubei et al.
NATURE METHODS (2010)
Fast and accurate short read alignment with Burrows-Wheeler transform
Heng Li et al.
BIOINFORMATICS (2009)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Epigenetics in human disease and prospects for epigenetic therapy
G Egger et al.
NATURE (2004)
Share Paper
